Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Source: Addressing Evolving Educational Needs on BTK Inhibitor Therapies in CLL/SLL and MCL
Listen to experts answer questions from a live CCO webinar on best practices in the use of approved BTK inhibitors for treating patients with CLL and MCL and potential uses of emerging investigational BTK inhibitors for these malignancies.
Jeff P. Sharman, MD
Program Director
Matthew S. Davids, MD, MMSc
Anthony Mato, MD, MSCE
Released: March 31, 2022

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

  • For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
  • What is the optimal therapy for a patient with del(17p) CLL?
  • When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
  • What are best practices in the use of BTK inhibitors for patients with MCL?
  • How can BTK inhibitor resistance occur?
  • How might investigational noncovalent BTK inhibitors be used should they be approved?

What are key adverse events with BTK inhibitors?

Information on this Educational Activity

Program Director

Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Lilly, Pharmacyclics, and TG Therapeutics and consulting fees from AbbVie, AstraZeneca, Genentech, Lilly, Pharmacyclics, and TG Therapeutics.

Faculty

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids MD, MMSc, has disclosed that he has received funds for research support from AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem and consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis.
Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Nurix, Loxo, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 17, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings